Harnessing oncolytic virus-mediated anti-tumor immunity

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Schirrmacher, Volker ^a,b   Fournier, Philippe ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b IOZK   (Germany)

Author keywords

Aanti viral response; Anti tumor activity; Immunotherapeutic approaches; Immunovirotherapy; Oncolytic virotherapy; Oncolytic virus; Tumor associated antigen

Indexed keywords

BISPECIFIC ANTIBODY; ONCOLYTIC PARVOVIRUS; ONCOLYTIC VIRUS; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CELL DEATH; EDITORIAL; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; SAFETY; T LYMPHOCYTE; THERAPY EFFECT; TUMOR IMMUNITY; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84915784210     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00337     Document Type: Editorial

References (12)

1. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol (2014) 4:74. doi: 10.3389/fonc.2014.00074
2. Thorne SH. Immunotherapeutic potential of oncolytic vaccinia virus. Front Oncol (2014) 4:155. doi:10.3389/fonc.2014.00155
3. Gujar SA, Lee PWK. Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol (2014) 4:77. doi:10.3389/fonc.2014.00077
4. Woller N, Gürlevik E, Ureche C-I, Schumacher A, Kühnel F. Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 4:188. doi:10.3389/fonc.2014.00188
5. Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR, et al. Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1. Front Oncol (2014) 4:92. doi:10.3389/fonc.2014.00092
6. Janelle V, Lamarre A. How informative is the immune response against surrogate tumor antigens to assess antitumor immunity? Front Oncol (2014) 4:135. doi:10.3389/fonc.2014.00135
7. Bauzon M, Hermiston T. Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. Front Immunol (2014) 5:74. doi:10.3389/fimmu.2014.00074
8. Schirrmacher V, Fournier P. Multimodal cancer therapy involving oncolytic Newcastle Disease Virus, autologous immune cells and bispecific antibodies. Front Oncol (2014) 4:224. doi:10.3389/fonc.2014.00224
9. Tai L-H, Auer R. Attacking postoperative metastases using perioperative oncolytic viruses and viral vaccines. Front Oncol (2014) 4:217. doi:10.3389/fonc.2014.00217
10. Altomonte J, Ebert O. Sorting out Pandora's box: discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma. Front Oncol (2014) 4:85. doi:10.3389/fonc.2014.00085
11. Forbes NE, Krishnan R, Diallo J-S. Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. Front Oncol (2014) 4:191. doi:10.3389/fonc.2014.00191
12. Nguyen A, Ho L, Wan Y. Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer. Front Oncol (2014) 4:145. doi:10.3389/fonc.2014.00145